45 results about "Placenta Growth Factor" patented technology

Disclosed is a method for diagnosing whether a subject suffers from a mild or severe form of liver cirrhosis based on determining the amount of GDF-15 (growth differentiation factor 15), PlGF (placental growth factor), and / or hepatocyte growth factor (HGF) in a sample from the subject and comparing the thus determined amount(s) with a reference amount (reference amounts). The method may further include determining the amount of adiponectin in a sample from the subject, and comparing the amount to a reference amount for adiponectin. Also described is a method to identifying a subject being susceptible to liver transplantation including determining the amount of GDF-15, PlGF, and / or HGF in a sample from the subject and comparing the thus determined amount(s) with a reference amount (reference amounts).

The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.

The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.

The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.

The present invention relates to a method for determining a risk whether an individual will suffer from a cardiovascular adverse event as a consequence of cardiac stress testing, comprising the steps of (a) measuring, preferably in vitro, the level of placenta growth factor, wherein (b) if the level of the placenta growth factor is at least increased, then the individual is at least at risk of suffering from an adverse event as a consequence of cardiac stress testing. In a further embodiment, additionally another marker is measured, particularly a natriuretic peptide, most particularly NT-proBNP. The present invention allows to stratify patients according to the environment and conditions under which cardiac stress testing should be carried out.

Disclosed is a method for identifying a subject being susceptible to a therapy for intensive glycemic control, the subject suffering from diabetes and being in need for a therapy for intensive glycemic control, based on determining the amount of PLGF (placental growth factor) in a sample of the subject and comparing the thus determined amount to a reference amount. In a preferred embodiment, the method further includes determining at least one further marker selected from the group consisting of a cardiac troponin and a natriuretic peptide and comparing the determined amount(s) to a reference amount (amounts). Moreover, disclosed is a method for predicting the risk of an acute cardiovascular event in a subject who suffers from diabetes and is on intensive glycemic control. Further disclosed is a kit and a device adapted to carry out the method of the present invention.

The invention discloses essential oil handmade soap with effects of cooling, moisturizing and cleaning skin. The essential oil handmade soap comprises, by weight, 35-45 parts of sodium cocoyl glutamate, 10-15 parts of flower and plant essential oil, 5-8 parts of tea polyphenol, 3-6 parts of lycium barbarum polysaccharide, 1-3 parts of lotus leaf extract, 1-3 parts of radix scrophulariae extract, 12-15 parts of trehalose, 7-10 parts of glutathione, 3-5 parts of vitamins, 30-35 parts of grape seed oil, 15-20 parts of palm kernel oil, 7-10 parts of castor oil, 1-2 parts of olive oil, 1.5-2.5 parts of sodium hydroxide, 5-8 parts of phosphatidylcholine bilayer, 1-2 parts of superoxide dismutase, 0.5-1 part of a placenta growth factor, 2-3 parts of royal jelly, 1-2 parts of 1, 2-propylene glycol, 2-3 parts of hydroxyethyl urea, 1-2 parts of carbomer and 2-3 parts of sodium lactate. The essential oil handmade soap has effects of deep cleaning skin, softening skin, reducing skin pruritus, balancing skin pH, supplying water, fading wrinkles, promoting shrinkage of enlarged pores of skin and keeping water-oil balance.

The present invention relates to a vascular endothelial growth factor fusion protein. The present invention relates to a fusion protein binding to a vascular endothelial growth factor (VEGFR) and / or a placental growth factor (PLGF). The fusion protein of the present invention comprises (a) a Fc domain of IgG1, wherein two heavy chains are linked by disulfide bond, and (b) four immunoglobulin domain2s of the VEGFR1, wherein two immunoglobulin domain2s are sequentially fused to each heavy chain of the Fc domain of (a). The present fusion protein has excellent activities of inhibiting cell migration and cell invasion, and has highly enhanced growth inhibition effects to various carcinomas and fibroblasts. Therefore, the fusion protein of the present invention can be used in the preparation of an agent for treating cancers or ocular diseases.

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.

Process for extracting and purifying the recombinant Placental Growth Factor (PLGF) expressed in inducible prokaryotic expression systems comprising the following steps: I) fermentation of the bacterial cells, II) extraction and purification of the inclusion bodies, III) renaturation of the expressed protein, IV) ion-exchange chromatography, V) reverse-phase chromatography.

The present invention provides a method for the diagnosis of disorders caused by foetal alcohol syndrome, said method comprising the assaying of PLGF (placental growth factor).

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.

This invention relates to compositions and methods for the treatment or prophylaxis of glaucoma and ocular hypertension, and for lowering of intraocular pressure. The invention provide VEGFR-1 agonists and combinations of vascular endothelial growth factor B (VEGF-B) with placenta growth factor (PLGF), ‘ Secreted protein acidic cysteine-rich’ (SPARC) antagonists, insulin, insulin like growth factor, their isoforms, their analoges, their gene-engineered modifications. Furthermore, the formentioned compositions and combinations are provided for coadministration with antiglaucoma agents, currently in clinical use, for the treatment or prophylaxis of glaucoma and ocular hypertension, for lowering of intraocular pressure, for increasing success rate of surgical procedures for the treatment or prophylaxis of glaucoma, and for preserving retinal ganglion cells.

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.

The invention relates to a soluble fms-like tyrosine kinase-1 detection kit as well as a preparation method and application thereof, the inventor detects soluble fms-like tyrosine kinase-1 by adopting a double-antibody sandwich method combined with a magnetic particle chemiluminescence technology, and finds that an immune micro-magnetic particle preparation method optimized by the inventor is adopted. A soluble fms-like tyrosine kinase-1 chemiluminescence immunoassay kit is formed by the prepared placenta growth factor capture antibody magnetic particles and an alkaline phosphatase labeled placenta growth factor detection antibody which is further prepared by the inventor through cross-linking agents DTBP and DTT and a sealing agent MMTS in a specific proportion. According to the present invention, the detection can be automatically completed by using the full-automatic chemiluminescence immunoassay analyzer as the detection tool, the detection performance is significantly improved, the detection sensitivity achieves 0.97 pg / mL, and the detection linear range is wide and can achieve 10-85000 pg / mL. Therefore, the method has a wide detection application prospect.

Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.

The invention relates to a single chain antibody of human anti-placenta growth factor, which is encoded by a heavy-chain gene with an SEQ NO.1 sequence and light-chain gene with an SEQ NO.2 sequence.The invention also provides a preparation method thereof, comprising the following steps in sequence: amplifying human total RNA heavy-chain variable region, light-chain variable region and constant region gene of the whole set by a PCR technique, splicing and constructing an overall-length single-chain antibody cDNA library; expressing the cDNA library by an externally-coupled transcription / translation system to obtain an antibody-ribosome-mRNA compound; performing affiliation selection and clution on the compound by a magnetic bead coated by specific antigen; amplifying selected destinationantibody gene by the PCR technique; and expressing the amplified antibody gene using the externally-coupled transcription / translation system repeatedly to obtain the single-chain antibody. The antibody is adapted to prepare medicament for treating ovarian cancer.

The invention provides a placenta growth factor quality control product and a preparation method thereof. The placenta growth factor quality control product comprises a placenta growth factor antigen, newborn calf serum, BSA and / or casein, glycerin and / or Tween 80, mannitol and / or xylitol and a preservative. The placenta growth factor quality control product disclosed by the invention is simple in preparation method, high in accuracy, high in precision and good in stability, can be applied to a fluorescence immunoassay platform of a POCT system, and is suitable for placenta growth factor detection kits clinically common on the platform. A quality control substance is provided for placenta growth factor kit evaluation and indoor and interventricular quality evaluation in clinical laboratories.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta-1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries.

The invention discloses a preparation method of a chemical luminescence kit for placenta growth factors. The preparation method comprises the following steps of preparing streptavidin magnetic particles, and preparing a streptavidin magnetic particle suspension liquid, preparing a placenta growth factor marked by biotin, preparing a placenta growth factor antibody marked by a chemical luminescencesubstance and the like; the streptavidin magnetic particles have high affinity between streptavidin and biotin, so that any biotin-labeled molecules can be bound, and the streptavidin magnetic particles can be used for immunization and molecular detection; the preparation method adopts the polystyrene magnetic particles, and has the characteristics of uniform particle size, large specific surfacearea and regular morphology, so that the target molecule can be rapidly and efficiently captured and magnetic separation is realized; and the magnetic particle chemiluminescence method provided by the invention has strong specificity, accuracy and quickness, short in detection time, accurate in detection result, high in repeatability and the like.

The invention belongs to the field of biological technique, i.e. gene recombination engineering. Placental growth factors (PLGFs) play important roles in neovascularization and vascular proliferation; however, natural PLGF content in vivo is low and the natural PLGFs have short half-times, thus to extract sufficient entogenous PLGF proteins so as to satisfy the increasingly demands of experimental study and clinical practice is difficult. The invention discloses a method for efficiently expressing, producing and recombining a PLGF system in vitro by gene recombination engineering and cell culture technology and for extracting and purifying the PLGF proteins from expressed supernatant by chromatographic separating technology. The invention also discloses a nonradioactive chemical coupling labeling treatment method for the purified PLGF proteins in vitro. The PLGF proteins (including the unlabeled or the chemical coupling labeled) have wide application in the experimental study and the clinical practice.

The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant PLGF protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset. The present invention also provides exemplary recombinant PLGF proteins including monomeric, dimeric and single-chain PLGF proteins.

The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of an anti-PlGF antibody or fragment thereof.